Conclusions
Based on the data presented, CCL17 could be a therapeutic target in OA patients with joint injury alone or with obesity.
Results
Therapeutic administration of B293 results in a dramatic amelioration of DMM-induced OA pain-like behaviour and the inhibition of disease progression, compared to BM4 (isotype control) treatment. A similar therapeutic effect was observed in HFD-exacerbated OA pain-like behaviour and disease. B293 treatment did not alter the measured HFD-induced metabolic changes. Conclusions: Based on the data presented, CCL17 could be a therapeutic target in OA patients with joint injury alone or with obesity.